Isoflurophate

Summary

Isoflurophate (CHEMBL1025) is an approved small molecule (ATC S01EB07); indicated across 1 condition including glaucoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01EB07
• Indications: 1 condition
• Chemistry: 184.15 Da · C6H14FO3P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1025
Name	Isoflurophate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5936
ChEBI	CHEBI:17941
ATC	S01EB07
Molecular formula	C6H14FO3P
Molecular weight	184.15
InChIKey	MUCZHBLJLSDCSD-UHFFFAOYSA-N

SMILES: CC(C)OP(=O)(OC(C)C)F

IUPAC name: 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane

Also known as: Floropryl, Fluostigmine, Isoflurophate, NSC-727370, diisopropyl fluorophosphate, di-isopropylfluorophosphate, diisopropyl phosphorofluoridate, Diisopropylfluorophosphate, ISOFLUROPHATE, SID50113285, SID144206196, DIISOPROPYL FLUOROPHOSPHATE

Patent coverage: 3,750 distinct patent families (13,137 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Acetylcholinesterase, Liver carboxylesterase, Acetylcholinesterase, Acetylcholinesterase, Lysosomal protective protein.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q29550	7.3	IC50	50	nM	CHEMBL_ACT_1836474
ACHE	6.92	IC50	120	nM	CHEMBL_ACT_3119866
O42275	6.32	IC50	480	nM	CHEMBL_ACT_1083078
ACHE	5.22	Ki	6000	nM	CHEMBL_ACT_3119867
CTSA	5	IC50	10000	nM	CHEMBL_ACT_1836468

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).